Most recently, heterozygous mutations of the SLC34A3 gene have been identified in individuals with milder clinical symptoms, including isolated hypercalciuria, mild hypophosphatemia, and elevated 1,25‐dihydroxy vitamin D [1,25‐(OH) 2 D] (Dasgupta et al., 2014). This evidence concerns the gene SLC34A3 and Hypercalciuria.